RA Patients May Safely Reduce DMARD Doses Without Worsening Symptoms
A trial found nearly 90% of rheumatoid arthritis patients on targeted therapies could cut their dose by half without worsening disease activity. Researchers say this suggests dose reductions may be an option for some patients.
This may affect RA patients on DMARDs and highlights findings from a randomized trial.
- population
- patients with rheumatoid arthritis (RA) well controlled on targeted therapies
Taken from the source as published — check the details before acting on them.
Study design and population
The trial involved patients with rheumatoid arthritis who were well controlled on targeted therapies and tested whether reducing their DMARD doses by half would affect their condition.
Outcome measured
Researchers assessed whether disease activity worsened after the dosage reduction, finding that most patients maintained stable disease control.
Common questions
What type of study was this?
This was a randomized trial conducted by South Korean researchers.
Sources
- Can DMARD Doses Be Safely Reduced for RA Patients? Korean Trial Says Yes. MedPage Today · medpagetoday.com
Headlines and links belong to the publishers listed above. The summary above is written by The Health Brief; see how this works.
